CONFLICTS OF INTEREST
Dr. M.H. Cnossen’s institution has received investigator-initiated
research and travel grants as well as speaker fees over the years from
the Netherlands Organisation for Scientific Research (NWO) and
Netherlands National research Agenda (NWA), the Netherlands Organization
for Health Research and Development (ZonMw), the Dutch Innovatiefonds
Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/ Takeda,
Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk,
Novartis, Roche, and Nordic Pharma, and for serving as a steering board
member for Roche, Bayer and Novartis. All grants and fees go to the
Erasmus MC as an institution. She is coordinator of Erasmus MC as a
Health Care Provider within the European Reference Network (ERN) for
rare hematological diseases EuroBloodNet and (co)leader of the local
Erasmus MC Expert Centers for Rare Bleeding Disorders and Sickle Cell
and Thalassemia Comprehensive Care Center.
R.A.A.M. has received grants from governmental and societal research
institutes such as NWO, ZonMW, Dutch Kidney Foundation and Innovation
Fund and unrestricted investigator research grants from Baxter/ Baxalta/
Shire/Takeda, Bayer, CSL Behring, Sobi and CelltrionHC. He has served as
advisor for Bayer, CSL Behring, Merck Sharp & Dohme, Baxter/ Baxalta/
Shire/Takeda. All grants and fees paid to the institution.
F.W.G. Leebeek has received unrestricted grants from CSL Behring,
Takeda, Sobi and uniQure. He is a consultant for CSL Behring, Takeda,
Biomarin and uniQure, of which the fees go to the University. He was
DSMB member of a study sponsored by Roche.
M. Coppens has received financial support for research from Bayer, CSL
Behring, Roche and Novo Nordisk, and honoraria for lecturing or
consultancy from Alexion, Bayer, CSL Behring, Daiichi Sankyo, Sobi and
Viatris.
Other authors have no conflict of interest to declare for this paper.